Management	management	O	O
strategies	strategies	O	O
for	for	O	O
ribavirin-induced	ribavirin-induced	O	O
hemolytic	hemolytic	O	B_disease
anemia	anemia	O	S_disease
in	in	O	O
the	the	O	O
treatment	treatment	O	O
of	of	O	O
hepatitis	hepatitis	O	B_disease
C	c	O	I_disease
:	:	O	O
clinical	clinical	O	O
and	and	O	O
economic	economic	O	O
implications	implications	O	O
.	.	O	O

OBJECTIVES	objectives	O	O
:	:	O	O
Recently	recently	O	O
published	published	O	O
studies	studies	O	O
have	have	O	O
demonstrated	demonstrated	O	O
increased	increased	O	O
efficacy	efficacy	O	O
and	and	O	O
cost-effectiveness	cost-effectiveness	O	O
of	of	O	O
combination	combination	O	O
therapy	therapy	O	O
with	with	O	O
interferon	interferon	O	O
and	and	O	O
alpha-2b/ribavirin	alpha-2b/ribavirin	O	O
compared	compared	O	O
with	with	O	O
interferon-alpha	interferon-alpha	O	O
monotherapy	monotherapy	O	O
in	in	O	O
the	the	O	O
treatment	treatment	O	O
of	of	O	O
chronic	chronic	O	B_disease
hepatitis	hepatitis	O	B_disease
C	c	O	I_disease
(	(	O	O
CHC	chc	O	O
)	)	O	O
.	.	O	O

Combination	combination	O	O
therapy	therapy	O	O
is	is	O	O
associated	associated	O	O
with	with	O	O
a	a	O	O
clinically	clinically	O	O
important	important	O	O
adverse	adverse	O	O
effect	effect	O	O
:	:	O	O
ribavirin-induced	ribavirin-induced	O	O
hemolytic	hemolytic	O	B_disease
anemia	anemia	O	S_disease
(	(	O	O
RIHA	riha	O	O
)	)	O	O
.	.	O	O

The	the	O	O
objective	objective	O	O
of	of	O	O
this	this	O	O
study	study	O	O
was	was	O	O
to	to	O	O
evaluate	evaluate	O	O
the	the	O	O
direct	direct	O	O
health-care	health-care	O	O
costs	costs	O	O
and	and	O	O
management	management	O	O
of	of	O	O
RIHA	riha	O	O
during	during	O	O
treatment	treatment	O	O
of	of	O	O
CHC	chc	O	O
in	in	O	O
a	a	O	O
clinical	clinical	O	O
trial	trial	O	O
setting	setting	O	O
.	.	O	O

METHODS	methods	O	O
:	:	O	O
A	a	O	O
systematic	systematic	O	O
literature	literature	O	O
review	review	O	O
was	was	O	O
conducted	conducted	O	O
to	to	O	O
synthesize	synthesize	O	O
information	information	O	O
on	on	O	O
the	the	O	O
incidence	incidence	O	O
and	and	O	O
management	management	O	O
of	of	O	O
RIHA	riha	O	O
.	.	O	O

Decision-analytic	decision-analytic	O	O
techniques	techniques	O	O
were	were	O	O
used	used	O	O
to	to	O	O
estimate	estimate	O	O
the	the	O	O
cost	cost	O	O
of	of	O	O
treating	treating	O	O
RIHA	riha	O	O
.	.	O	O

Uncertainty	uncertainty	O	O
was	was	O	O
evaluated	evaluated	O	O
using	using	O	O
sensitivity	sensitivity	O	O
analyses	analyses	O	O
.	.	O	O

RESULTS	results	O	O
:	:	O	O
RIHA	riha	O	O
,	,	O	O
defined	defined	O	O
as	as	O	O
a	a	O	O
reduction	reduction	O	O
in	in	O	O
hemoglobin	hemoglobin	O	O
to	to	O	O
less	less	O	O
than	than	O	O
100	100	O	O
g/L	g/l	O	O
,	,	O	O
occurs	occurs	O	O
in	in	O	O
approximately	approximately	O	O
7	7	O	O
%	%	O	O
to	to	O	O
9	9	O	O
%	%	O	O
of	of	O	O
patients	patients	O	O
treated	treated	O	O
with	with	O	O
combination	combination	O	O
therapy	therapy	O	O
.	.	O	O

The	the	O	O
standard	standard	O	O
of	of	O	O
care	care	O	O
for	for	O	O
management	management	O	O
of	of	O	O
RIHA	riha	O	O
is	is	O	O
reduction	reduction	O	O
or	or	O	O
discontinuation	discontinuation	O	O
of	of	O	O
the	the	O	O
ribavirin	ribavirin	S_chemical	O
dosage	dosage	O	O
.	.	O	O

We	we	O	O
estimated	estimated	O	O
the	the	O	O
direct	direct	O	O
cost	cost	O	O
of	of	O	O
treating	treating	O	O
clinically	clinically	O	O
significant	significant	O	O
RIHA	riha	O	O
to	to	O	O
be	be	O	O
 	 	O	O
170	170	O	O
per	per	O	O
patient	patient	O	O
receiving	receiving	O	O
combination	combination	O	O
therapy	therapy	O	O
per	per	O	O
48-week	48-week	O	O
treatment	treatment	O	O
course	course	O	O
(	(	O	O
range	range	O	O
 	 	O	O
68-	68-	O	O
692	692	O	O
)	)	O	O
.	.	O	O

The	the	O	O
results	results	O	O
of	of	O	O
the	the	O	O
one-way	one-way	O	O
sensitivity	sensitivity	O	O
analyses	analyses	O	O
ranged	ranged	O	O
from	from	O	O
 	 	O	O
57	57	O	O
to	to	O	O
 	 	O	O
317	317	O	O
.	.	O	O

In	in	O	O
comparison	comparison	O	O
,	,	O	O
the	the	O	O
cost	cost	O	O
of	of	O	O
48	48	O	O
weeks	weeks	O	O
of	of	O	O
combination	combination	O	O
therapy	therapy	O	O
is	is	O	O
 	 	O	O
16,459	16,459	O	O
.	.	O	O
CONCLUSIONS	conclusions	O	O
:	:	O	O
The	the	O	O
direct	direct	O	O
cost	cost	O	O
of	of	O	O
treating	treating	O	O
clinically	clinically	O	O
significant	significant	O	O
RIHA	riha	O	O
is	is	O	O
1	1	O	O
%	%	O	O
(	(	O	O
170/	170/	O	O
16,459	16,459	O	O
)	)	O	O
of	of	O	O
drug	drug	O	O
treatment	treatment	O	O
costs	costs	O	O
.	.	O	O

Questions	questions	O	O
remain	remain	O	O
about	about	O	O
the	the	O	O
optimal	optimal	O	O
dose	dose	O	O
of	of	O	O
ribavirin	ribavirin	S_chemical	O
and	and	O	O
the	the	O	O
incidence	incidence	O	O
of	of	O	O
RIHA	riha	O	O
in	in	O	O
a	a	O	O
real-world	real-world	O	O
population	population	O	O
.	.	O	O

Despite	despite	O	O
these	these	O	O
uncertainties	uncertainties	O	O
,	,	O	O
this	this	O	O
initial	initial	O	O
evaluation	evaluation	O	O
of	of	O	O
the	the	O	O
direct	direct	O	O
cost	cost	O	O
of	of	O	O
treating	treating	O	O
RIHA	riha	O	O
provides	provides	O	O
an	an	O	O
estimate	estimate	O	O
of	of	O	O
the	the	O	O
cost	cost	O	O
and	and	O	O
management	management	O	O
implications	implications	O	O
of	of	O	O
this	this	O	O
clinically	clinically	O	O
important	important	O	O
adverse	adverse	O	O
effect	effect	O	O
.	.	O	O

